Key Points {#FPar1}
==========

The long-term safety of dapagliflozin was similar between older and younger patients, with comparable rates of hypoglycaemia, genital infections and urinary tract infections, low rates of volume reduction, and no increased risk of bone fractures or falls.Adverse events of renal function were more frequent in patients receiving dapagliflozin and in older vs. younger patients; the majority of cases were non-serious and driven by small transient changes in serum creatinine.Dapagliflozin did not increase the risk of cardiovascular disease in older or younger patients.

Introduction {#Sec1}
============

The prevalence of type 2 diabetes mellitus (T2DM) is increasing globally, with the highest increases estimated amongst older populations \[[@CR1]\]. A 4.5-fold increase in diabetes is predicted between 2005 and 2050 in people aged ≥65 years, compared with a 3-fold rise in the overall population \[[@CR2]\].

Polypharmacy \[[@CR3]\] and multiple comorbidities \[[@CR4], [@CR5]\] among older patients with T2DM present a number of challenges in terms of the clinical management of this patient group. In addition, pharmacokinetic and pharmacodynamic changes associated with ageing may increase the risk of adverse events (AEs) among this age group \[[@CR5]\], including hypoglycaemia, volume reduction, impaired renal function and cardiovascular disease \[[@CR6]--[@CR8]\]. The increased susceptibility to hypoglycaemia among older people \[[@CR9]\] is of particular concern because of the associated increased risk of falls and bone fractures \[[@CR10]\].

Certain therapies may be less appropriate for some older patients, such as those associated with a higher risk of hypoglycaemia (e.g. sulphonylurea or insulin) \[[@CR6]\]. Furthermore, complex dosing regimens for glycaemic control are not favoured. A once-daily oral medication regimen that can be taken at any time of day with or without food, with a low risk of hypoglycaemia and a well-characterised predictable safety profile, would be preferable.

Novel glucose-lowering therapies are required to address the unmet needs in the treatment of older patients with T2DM. Dapagliflozin is a highly selective sodium glucose co-transporter 2 (SGLT2) inhibitor that, in addition to reducing glycosylated haemoglobin (HbA~1c~), body weight and systolic blood pressure \[[@CR11]--[@CR14]\], is associated with a low intrinsic risk of hypoglycaemia \[[@CR16]\], and showed no increase in cardiovascular risk in a recent meta-analysis \[[@CR15]\]. These benefits combined with its once-daily oral dosing regimen \[[@CR17]\] suggest it may be a useful treatment in the management of older patients with T2DM. Identified risks include genital infections and, to a lesser extent, urinary tract infections and non-serious volume-related events; all of which are consistent with the mechanism of action of dapagliflozin and are mostly of mild intensity \[[@CR16]\].

Here, we present a pooled analysis of nine phase III studies to assess the long-term safety of dapagliflozin in older patients with T2DM. In addition, we present a pooled analysis of 21 phase IIb/III studies to assess the cardiovascular safety of dapagliflozin in older patients with T2DM.

Methods {#Sec2}
=======

Patient Population {#Sec3}
------------------

Safety and efficacy were evaluated by age group \[\<65, ≥65 and ≥75 years (a subpopulation of the ≥65 years age group; safety only)\] in a placebo-controlled pool of nine double-blind phase III studies of ≤104 weeks in duration, in which patients with T2DM received dapagliflozin 10 mg (*n* = 2026) or placebo (*n* = 1956) ± background glucose-lowering therapy (Online Resource 1).

Cardiovascular events were evaluated by age group \[\<65, ≥65 and ≥75 years (a subpopulation of the ≥65 years age group)\], using data from a pre-specified cardiovascular meta-analysis of 21 phase IIb/III studies of ≤208 weeks in duration, in which patients with T2DM received dapagliflozin (2.5, 5, 10, 20 or 50 mg; *n* = 5936) or control (placebo or comparator treatment; *n* = 3403) ± background glucose-lowering therapy (Online Resource 2). Studies with at least one adjudicated cardiovascular event were included in the analysis.

These two different patient pools were each selected to address a specific objective. The nine-study pool was considered to be the most appropriate to assess general safety because all trials were long term (with at least 48 weeks of blinded study treatment) and placebo controlled. In contrast, the 21-study pool with high patient numbers was considered to be the most appropriate to assess the cardiovascular profile of dapagliflozin because cardiovascular events were relatively infrequent. The nine-study safety pool examined dapagliflozin 10 mg (the usual recommended clinical dose), whereas the 21-study cardiovascular pool examined all dapagliflozin doses (2.5, 5, 10, 20 and 50 mg). Methods for each individual study in these pools have been published previously \[[@CR11]--[@CR14], [@CR18]--[@CR32]\]. All studies were conducted according to the principles of the Declaration of Helsinki and the requirements of Good Clinical Practice, and were approved by the relevant institutional review boards/ethics committees. All participants gave written informed consent.

General Safety Outcomes {#Sec4}
-----------------------

### Adverse Events {#Sec5}

The frequency of overall AEs and serious AEs (SAEs) was evaluated according to age group up to 104 weeks.

### Adverse Events of Special Interest {#Sec6}

The proportion of patients with any event of hypoglycaemia was assessed by age and according to background medication, up to 104 weeks.

The frequency of AEs of genital infection, urinary tract infection (UTI), volume reduction (defined as hypotension, dehydration or hypovolaemia), bone fracture, fall and renal function were evaluated by age group up to 104 weeks, based on pre-defined lists of preferred terms from the *Medical Dictionary of Regulatory Activities* (version 15.1) (Online Resource 3). Reports of genital infections and UTIs were obtained through proactive questioning and spontaneous reporting. Calculation of estimated glomerular filtration rate (eGFR) used the Abbreviated Modification of Diet in Renal Disease Study equation \[[@CR33]\]. Mean change from baseline in eGFR was determined for each age group up to 104 weeks, as were the maximum changes from baseline in serum creatinine in patients with at least one AE of renal function.

### Laboratory Values {#Sec7}

The frequency of marked abnormalities (MAs) in laboratory values was assessed for each age category up to 104 weeks. Laboratory assessments comprised the following: serum calcium, serum bicarbonate, serum potassium, serum magnesium, serum sodium, inorganic phosphorus, haematocrit, blood urea nitrogen and serum creatinine.

Efficacy Outcomes {#Sec8}
-----------------

### HbA~1c~, Body Weight and Systolic Blood Pressure {#Sec9}

Efficacy assessments for each age group comprised the mean change from baseline in HbA~1c~, the proportion of patients achieving an HbA~1c~ level of \<53 mmol/mol (\<7 %) and the mean change from baseline in body weight and systolic blood pressure (SBP), up to 104 weeks.

Analysis Method {#Sec10}
---------------

Analyses were conducted using descriptive statistics only. Comparisons with placebo were adjusted for differences in baseline values between groups. Analyses were performed using all available data regardless of rescue therapy, with the exception of hypoglycaemia and efficacy data \[change from baseline in HbA~1c~, body weight and SBP, and the proportion of patients achieving an HbA~1c~ level of \<53 mmol/mol (\<7 %)\], which excluded data after the initiation of rescue therapy. Confidence intervals (CIs) for the proportion of patients achieving an HbA~1c~ level of \<53 mmol/mol (\<7 %) were estimated using logistic regression modelling for the difference between treatment groups.

Cardiovascular Safety {#Sec11}
---------------------

A meta-analysis was conducted according to age group to assess the cardiovascular risk for the pooled population of 21 phase IIb/III studies of ≤208 weeks in duration, using the composite endpoint of 'cardiovascular death, myocardial infarction, stroke and hospitalisation for unstable angina'. All cardiovascular events were independently adjudicated in a blinded manner. The analyses were conducted without statistical hypothesis testing. Hazard ratios (HRs) and 95 % CIs comparing total dapagliflozin doses (2.5, 5, 10, 20 and 50 mg) with a control (placebo or comparator treatment) were calculated for each age group using the Cox proportional hazards model. An upper limit of the 95 % CI of \<1 (the null value) would indicate that dapagliflozin was associated with a lower cardiovascular risk than placebo, whereas a lower limit of the 95 % CI of \>1 would indicate that dapagliflozin was associated with a higher cardiovascular risk than placebo.

Results {#Sec12}
=======

Patients {#Sec13}
--------

Demographics and baseline characteristics for the nine pooled studies were generally balanced between the dapagliflozin and placebo groups in patients aged \<65 and ≥65 years (Table [1](#Tab1){ref-type="table"}). Some differences were observed between the treatment groups in patients aged ≥75 years (Table [1](#Tab1){ref-type="table"}), which may reflect the small sample size for this age group (*n* = 97 for dapagliflozin vs. *n* = 77 for placebo) and random variation within the ≥75 years dataset rather than significant differences between the groups. Older patients (≥65 or ≥75 years) had a relatively longer T2DM duration, higher systolic blood pressure and lower eGFR levels at baseline than younger patients (\<65 years) (Table [1](#Tab1){ref-type="table"}).Table 1Demographic and baseline characteristics by age groupAge \<65 yearsAge ≥65 yearsAge ≥75 years^a^Dapagliflozin 10 mg (*n* = 1406)Placebo (*n* = 1301)Dapagliflozin 10 mg (*n* = 620)Placebo (*n* = 655)Dapagliflozin 10 mg (*n* = 97)Placebo (*n* = 77)Mean age, years (SD)54.6 (7.5)54.8 (7.5)69.9 (4.0)69.7 (4.0)77.1 (1.8)77.8 (2.8)Female, *n* (%)624 (44.4)545 (41.9)228 (36.8)254 (38.8)43 (44.3)31 (40.3)Race, *n* (%) Caucasian1179 (83.9)1090 (83.8)560 (90.3)605 (92.4)90 (92.8)72 (93.5) Asian96 (6.8)94 (7.2)35 (5.6)26 (4.0)6 (6.2)3 (3.9) Black/African American57 (4.1)50 (3.8)9 (1.5)11 (1.7)1 (1.0)1 (1.3) Other74 (5.3)67 (5.1)16 (2.6)13 (2.0)01 (1.3)Mean time from T2DM diagnosis, years (SD)8.3 (7.3)8.3 (7.0)13.2 (8.9)12.7 (8.8)15.4 (10.2)14.9 (10.0)Mean HbA~1c~, mmol/mol (SD)65 (9.6)65 (9.5)64 (8.9)64 (8.7)65 (8.6)62 (7.4)Mean FPG, mmol/L (SD)9.1 (2.5)9.2 (2.5)8.9 (2.5)8.8 (2.3)8.8 (2.3)8.6 (2.0)Mean weight, kg (SD)92.1 (20.3)91.6 (19.9)89.3 (17.8)89.5 (17.1)84.9 (13.7)88.2 (15.1)Mean BMI, kg/m^2^ (SD)32.8 (5.9)32.5 (6.0)31.7 (4.9)32.0 (5.2)30.7 (4.6)31.9 (4.6)Mean systolic BP, mmHg (SD)130.5 (15.2)130.1 (15.0)135.7 (14.7)135.5 (13.9)138.7 (14.5)133.3 (13.8)Systolic BP, *n* (%) ≥130 mmHg738 (52.5)677 (52.0)415 (66.9)427 (65.2)71 (73.2)49 (63.6)Mean eGFR, mL/min/1.73 m^2^ (SD)84.6 (19.0)84.3 (19.2)72.8 (16.7)73.4 (16.9)72.6 (16.2)68.6 (16.5)eGFR, *n* (%) \<30 mL/min/1.73 m^2b^01 (0.1)1 (0.2)000 ≥30 to \<60 mL/min/1.73 m^2c^117 (8.3)108 (8.3)134 (21.6)141 (21.5)22 (22.7)22 (28.6) ≥60 to \<90 mL/min/1.73 m^2d^754 (53.6)710 (54.6)386 (62.3)403 (61.5)57 (58.8)47 (61.0) ≥90 mL/min/1.73 m^2e^535 (38.1)481 (37.0)99 (16.0)111 (16.9)18 (18.6)8 (10.4)Mean serum creatinine, µmol/L (SD)77.5 (18.7)78.3 (20.9)85.8 (21.8)84.7 (19.5)82.4 (18.3)87.9 (20.2)Data available up to 104 weeks*BMI* body mass index, *BP* blood pressure, *eGFR* estimated glomerular filtration rate, *FPG* fasting plasma glucose, *HbA* ~*1c*~ glycosylated haemoglobin, *SD* standard deviation, *T2DM* type 2 diabetes mellitus^a^Subpopulation of the ≥65 years age group^b^Severe renal impairment^c^Moderate renal impairment^d^Mild renal impairment^e^Normal renal function

Overall Adverse Events {#Sec14}
----------------------

Overall AEs and discontinuations owing to AEs were more common in patients aged ≥65 and ≥75 years than in patients aged \<65 years, and were more frequent with dapagliflozin than placebo (Table [2](#Tab2){ref-type="table"}). The frequency of SAEs was similar between the treatment groups across all ages, and more frequent in older vs. younger patients. In total, 30 deaths were reported in the nine pooled studies; 18/2026 (0.9 %) in the dapagliflozin group and 12/1956 (0.6 %) in the placebo group (Table [2](#Tab2){ref-type="table"}), none of which were considered related to treatment. Further information regarding these deaths is provided in Online Resource 4.Table 2Adverse events by age group*n* (%)Age \<65 yearsAge ≥65 yearsAge ≥75 years^a^Dapagliflozin 10 mg (*n* = 1406)Placebo (*n* = 1301)Dapagliflozin 10 mg (*n* = 620)Placebo (*n* = 655)Dapagliflozin 10 mg (*n* = 97)Placebo (*n* = 77)AEs All1028 (73.1)920 (70.7)480 (77.4)479 (73.1)78 (80.4)58 (75.3) AE leading to discontinuation83 (5.9)65 (5.0)89 (14.4)80 (12.2)26 (26.8)17 (22.1) Any SAE^b^154 (11.0)154 (11.8)124 (20.0)132 (20.2)19 (19.6)14 (18.2) Deaths7 (0.5)7 (0.5)11 (1.8)5 (0.8)2 (2.0)1 (1.3)AEs of special interest Hypoglycaemia  All253 (18.0)174 (13.4)125 (20.2)116 (17.7)17 (17.5)13 (16.9)  Major episodes^c^2 (0.1)2 (0.2)2 (0.3)000 Genital infection  All115 (8.2)13 (1.0)41 (6.6)6 (0.9)7 (7.2)0  Female78 (12.5)12 (2.2)20 (8.8)3 (1.2)6 (14.0)0  Male37 (4.7)1 (0.1)21 (5.4)3 (0.7)1 (1.9)0  SAEs^b^000000 Urinary tract infection  All124 (8.8)71 (5.5)50 (8.1)50 (7.6)8 (8.2)7 (9.1)  Female93 (14.9)52 (9.5)28 (12.3)34 (13.4)4 (9.3)5 (16.1)  Male31 (4.0)19 (2.5)22 (5.6)16 (4.0)4 (7.4)2 (4.3)  SAEs^b^3 (0.2)2 (0.2)2 (0.3)1 (0.2)1 (1.0)0 Pyelonephritis2 (0.1)1 (0.1)1 (0.2)2 (0.3)00 Volume reduction^d^  All24 (1.7)16 (1.2)14 (2.3)11 (1.7)3 (3.1)2 (2.6)  SAEs^b^1 (\<0.1)3 (0.2)2 (0.3)3 (0.4)01 (1.3)   Syncope1 (\<0.1)2 (0.2)1 (0.2)3 (0.5)01 (1.3)   Circulatory collapse01 (\<0.1)1 (0.2)000 Renal function  All49 (3.5)30 (2.3)87 (14.0)52 (7.9)29 (29.9)16 (20.8)  SAEs^b^4 (0.3)1 (0.1)1 (0.2)2 (0.3)1 (1.3)0Data available up to 104 weeks. All results included data after rescue therapy, apart from hypoglycaemia for which data after rescue therapy were excluded*AE* adverse event, *N* total number of patients, *n* number of patients with an AE, *SAE* serious adverse event^a^Subpopulation of the ≥65 years age group^b^Based on the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use definition^c^Symptomatic episode requiring external assistance, with a capillary or plasma glucose value \<54 mg/dL (3 mmol/L) and prompt recovery after glucose or glucagon administration^d^Hypotension, dehydration or hypovolaemia

Adverse Events of Special Interest {#Sec15}
----------------------------------

### Hypoglycaemia {#Sec16}

The frequency of hypoglycaemia was similar between younger patients (aged \<65 years) and older patients (aged ≥65 or ≥75 years), and more frequent with dapagliflozin than placebo, with major hypoglycaemic episodes being rare in all treatment groups (Table [2](#Tab2){ref-type="table"}). In patients receiving dapagliflozin as monotherapy or in combination with metformin, a thiazolidinedione or a dipeptidyl peptidase-4 inhibitor, the frequency of hypoglycaemia with dapagliflozin was similar to placebo for all age groups (Online Resource 5). Hypoglycaemia was more common in studies where treatment was combined with insulin or a sulphonylurea, with comparatively higher rates in dapagliflozin-treated patients than in placebo-treated patients.

### Genital Infection and Urinary Tract Infection {#Sec17}

Events of genital infection occurred more frequently with dapagliflozin than placebo but did not substantially differ between age groups (Table [2](#Tab2){ref-type="table"}). Events were more common among female patients regardless of age. All AEs of genital infection were reported to be mild or moderate in intensity and responded to standard treatment.

Although AEs of UTI were more common with dapagliflozin than placebo treatment in patients aged \<65 years, frequencies were similar between treatment groups in patients aged ≥65 and ≥75 years (Table [2](#Tab2){ref-type="table"}) and did not increase with age. AEs of UTI were more common among female patients. Most events of UTI were reported to be of mild or moderate intensity, and SAEs were rare for all age groups. Few cases of pyelonephritis were reported with dapagliflozin or placebo, regardless of age (Table [2](#Tab2){ref-type="table"}).

### Volume Reduction {#Sec18}

The frequency of AEs of volume reduction was low in both treatment arms across all age groups, with a small increase in events with dapagliflozin and in patients aged ≥75 years (Table [2](#Tab2){ref-type="table"}). Most volume reduction AEs were reported as hypotension or syncope. The majority of AEs of volume reduction were mild or moderate in intensity, did not require intervention and had resolved within 28 days \[number of events (%) with a duration \>28 days: \<65 years: *n* = 8/30 (26.7 %) vs. *n* = 0/17 (0.0 %); ≥65 years: *n* = 2/17 (11.8 %) vs. *n* = 0/12 (0.0. %); ≥75 years: *n* = 1/5 (20.0 %) vs. *n* = 0/2 (0.0 %), with dapagliflozin vs. placebo, respectively\]. Few SAEs of volume reduction were reported in either treatment group, without any obvious imbalance between groups; most SAEs were reported as syncope (Table [2](#Tab2){ref-type="table"}).

### Renal Function {#Sec19}

Renal function remained stable over time in patients treated with dapagliflozin (Fig. [1](#Fig1){ref-type="fig"}). In younger patients, eGFR returned to baseline within a few weeks of treatment after a small early reduction with dapagliflozin vs. placebo (−4.0 vs. 0.1 mL/min/1.73 m^2^ at week 1, respectively). In older patients, the initial reduction in eGFR was of a similar magnitude to younger patients (≥65 years: −4.7 vs. 0.9 mL/min/1.73 m^2^ at week 1; ≥75 years: −5.2 vs. 0.4 mL/min/1.73 m^2^ at week 4, with dapagliflozin and placebo, respectively); however, recovery of eGFR appeared slower, and levels remained below baseline but were stable up to 102 weeks. Interestingly, after the first 24 weeks of treatment, eGFR values were superimposable in patients receiving dapagliflozin and placebo (Fig. [1](#Fig1){ref-type="fig"}).Fig. 1Mean changes from baseline in eGFR over time by age group. Data available up to 102 weeks; includes data after rescue therapy. *BL* baseline, *CI* confidence interval, *eGFR* estimated glomerular filtration rate, *SD* standard deviation. ^a^Subpopulation of the ≥65 years age group

AEs of renal function were more common with dapagliflozin (Table [2](#Tab2){ref-type="table"}) and the frequency of events increased with age in both treatment groups. Most AEs of renal function were reports of increased creatinine levels, reduced creatinine clearance, renal impairment or reduced eGFR. Few SAEs of renal function were reported.

The distribution of serum creatinine changes in patients with a reported AE of renal function was similar between the treatment groups in patients aged \<65 and ≥65 years, with a higher frequency of minor, transient serum creatinine changes (9 to ≤27 µmol/L) reported with dapagliflozin in patients aged ≥75 years (Fig. [2](#Fig2){ref-type="fig"}).Fig. 2Maximum change from baseline in serum creatinine in patients with AEs of renal function, by age group. Data show the proportion of patients with a maximum change from baseline in serum creatinine in the range indicated. Data available up to 102 weeks; *n* is the number of patients with an AE of renal function; *N* is the number of treated patients. Includes data after rescue therapy. *AE* adverse event. ^a^Subpopulation of the ≥65 years age group

MAs of serum creatinine of ≥133 µmol/L were more frequent in older vs. younger patients, with a similar frequency between the dapagliflozin and placebo groups (Online Resource 6). MAs of serum creatinine of ≥221 µmol/L were uncommon in all age groups. MAs of blood urea nitrogen were balanced between the treatment groups regardless of age.

Bone Fractures, Falls and Non-renal Laboratory Abnormalities {#Sec20}
------------------------------------------------------------

The frequency of fractures was numerically similar or lower with dapagliflozin vs. placebo for all age groups \[\<65 years: 16 (1.1 %) vs. 14 (1.1 %); ≥65 years: 7 (1.1 %) vs. 18 (2.7 %); ≥75 years: 1 (1.0 %) vs. 2 (2.6 %), respectively\]. Dapagliflozin was not associated with an increased risk of falls compared with placebo in any age category \[\<65 years: 10 (0.7 %) vs. 9 (0.7 %); ≥65 years: 4 (0.6 %) vs. 14 (2.1 %); ≥75 years: 0 vs. 1 (1.3 %), respectively).

Electrolyte abnormalities were infrequent, and MAs in serum calcium, serum bicarbonate, serum magnesium and serum sodium were balanced between the treatment arms and across age groups (Online Resource 6). Dapagliflozin was associated with a higher frequency of serum potassium MAs of ≥6.0 mmol/L than placebo in older but not younger patients (Online Resource 6). No cases of serum potassium MAs of ≤2.5 mmol/L were reported. MAs of inorganic phosphorus (≥1.81 mmol/L) were more common with dapagliflozin and were more common in older vs. younger patients (Online Resource 6). MAs of haematocrit \>55 % were more common with dapagliflozin regardless of age.

Efficacy Outcomes {#Sec21}
-----------------

### HbA~1c~ {#Sec22}

Dapagliflozin was associated with a greater reduction from baseline in HbA~1c~ up to 104 weeks compared with placebo in both patients aged \<65 and those aged ≥65 years (Online Resource 7). A significantly greater proportion of patients achieved an HbA~1c~ value of \<53 mmol/mol (\<7 %), with dapagliflozin vs. placebo in both age groups (\<65 years: 25.6 vs. 15.2 %; ≥65 years: 18.2 vs. 12.3 %). As such, the efficacy of dapagliflozin in reducing HbA~1c~ was similar in older vs. younger patients.

### Body Weight and Systolic Blood Pressure {#Sec23}

For both patients aged \<65 years and those aged ≥65 years, reductions in body weight were greater with dapagliflozin than with placebo up to 104 weeks (Online Resource 8). SBP reduction was more pronounced with dapagliflozin compared with placebo in both age categories, although absolute changes were generally small (Online Resource 9).

Cardiovascular Risk {#Sec24}
-------------------

In the 21-study cardiovascular meta-analysis of ≤208 weeks \[dapagliflozin, *n* = 5936 vs. control (placebo or comparator treatment), *n* = 3403\], the HR for the composite endpoint of 'cardiovascular death, myocardial infarction, stroke and hospitalisation for unstable angina' was \<1 for dapagliflozin vs. control in all age groups (Fig. [3](#Fig3){ref-type="fig"}), indicating that dapagliflozin does not increase the risk of cardiovascular disease in these patients.Fig. 3Cardiovascular composite endpoint^a^ by age. Data available up to 208 weeks. An HR upper 95 % CI of \<1 would indicate that dapagliflozin was associated with longer cardiovascular composite-free survival than control. *n* is the number of patients who experienced a cardiovascular composite endpoint; *N* is the total number of treated patients. *CI* confidence interval, *DAPA* dapagliflozin, *HR* hazard ratio. ^a^Cardiovascular death, myocardial infarction, stroke and hospitalisation for unstable angina. ^b^Subpopulation of the ≥65 years age group

Discussion {#Sec25}
==========

This pooled analysis of nine phase III studies investigated the safety profile of dapagliflozin across age subgroups. Dapagliflozin 10 mg was generally well tolerated in both younger and older patients with T2DM during the 2-year treatment period. As expected, dapagliflozin was shown to reduce HbA~1c~, body weight and SBP compared with placebo across age groups.

Despite the fact that older patients are at higher risk of hypoglycaemia \[[@CR8]\], rates were generally comparable across all ages, with a higher frequency in the dapagliflozin group compared with the placebo group. Of note, older patients treated with dapagliflozin either as monotherapy or in combination with metformin, a thiazolidinedione or a dipeptidyl peptidase-4 inhibitor had a similar risk of hypoglycaemia as placebo, in line with previous studies showing that dapagliflozin is associated with a low intrinsic hypoglycaemic risk \[[@CR32], [@CR34]\].

The increased risk of genital infections with dapagliflozin 10 mg relative to placebo is consistent with previous observations of SGLT2 inhibitors \[[@CR35]\], but frequencies did not increase in older patients. These events are typical for diabetes and the risk, presentation and treatment options are familiar to both physicians and patients \[[@CR36]\]. Furthermore, despite the fact that older people are more susceptible to UTIs \[[@CR37]\], rates did not increase in older patients in the current analysis.

Dapagliflozin has a mild diuretic effect, and therefore volume-related events are of special interest, especially in older patients \[[@CR17]\]. Older patients have an increased propensity to develop volume reduction, which may be attributed to changes in body composition with ageing, leading to impairments in volume regulation and dysregulation of fluid intake \[[@CR38]\]. Volume reduction may also be exacerbated by the diuretic treatments taken by many older patients \[[@CR39]\]. AEs of volume reduction were more frequent with dapagliflozin 10 mg than placebo, and were higher in patients aged ≥75 years in both treatment groups. Most volume reduction events with dapagliflozin were reported as hypotension with no intervention required, which is consistent with previous reports \[[@CR16]\], and the vast majority of events were mild or moderate in intensity.

Renal function in older and younger patients treated with dapagliflozin remained stable over time, with small transient reductions in eGFR relative to placebo early on in treatment. Similar to observations made in patients with impaired renal function \[[@CR25]\], eGFR levels did not completely return to baseline levels in older patients, after an initial small drop in eGFR, which is consistent with the mechanism of action of dapagliflozin. These early small eGFR decreases followed by long-term stability across age groups are likely related to tubuloglomerular feedback responses and/or blood pressure reduction \[[@CR40]\], and should not lead to discontinuation of dapagliflozin treatment. Ageing is associated with a progressive decline in eGFR \[[@CR38]\] and slower renal function recovery times \[[@CR41]\], which may be attributed to an impaired capacity for autoregulation \[[@CR42]\]. In the current analysis, the fact that eGFR levels did not fully recover to baseline values in older patients, irrespective of treatment group, is in keeping with the reduced renal function in this population.

In view of the diuretic effect of dapagliflozin \[[@CR26]\] and some transient volume shifts, it is not surprising to see elevations in serum creatinine, especially in patients with renal impairment. AEs of renal function were more commonly reported in patients treated with dapagliflozin 10 mg than placebo and were more frequent in older patients than in younger patients, consistent with an increased susceptibility to AEs of renal function among this age group. Owing to their small magnitude, these changes were not considered to be clinically meaningful. Dapagliflozin was not associated with any electrolyte changes typical of conventional diuretics \[[@CR43]\], and did not increase the frequency of fractures or falls, regardless of age. Previous studies have shown that dapagliflozin does not affect bone mineral density or markers of bone formation and resorption \[[@CR44]\].

Dapagliflozin did not increase the risk of hyperkalaemia compared with placebo in younger patients (aged \<65 years), although a small increase was reported in older patients (aged ≥65 and ≥75 years). However, the majority of cases of hyperkalaemia were not reported as AEs. A previous pooled analysis in patients with T2DM demonstrated that dapagliflozin did not increase the risk of hyperkalaemia \[[@CR16]\], although the majority of patients in this analysis (\~70 %) were aged \<65 years. The higher frequency of hyperkalaemia in older patients observed in the current analysis may be partly related to an age-related decline in renal function and the increased use of potassium-altering medications among many older people compared with younger people \[[@CR45]\].

Older patients with T2DM are at considerable risk of cardiovascular complications \[[@CR5]\]. The data presented here provide reassurance regarding the cardiovascular safety of dapagliflozin and suggest a potential cardiovascular benefit, which is consistent with the multifactorial beneficial effects on cardiovascular risk factors associated with SGLT2 inhibitors. Indeed, a recent trial in patients with T2DM and established cardiovascular disease demonstrated significant improvements in cardiovascular outcomes with the SGLT2 inhibitor empagliflozin \[[@CR46]\]. Previous studies indicate that dapagliflozin has positive effects on a number of cardiovascular risk factors including weight loss and blood pressure reduction \[[@CR15], [@CR47]--[@CR49]\], which will be further investigated in a large randomised placebo-controlled trial assessing cardiovascular outcomes in a broad population of more than 17,000 patients with T2DM and established cardiovascular disease or in patients having multiple cardiovascular risk factors (DECLARE; clinicaltrials.gov ID NCT01730534).

Limitations to this pooled analysis include the low patient numbers in the ≥75 years age group (*n* = 174) in comparison with the other two age categories (≥65 years, *n* *=* 1275; \<65 years, *n* *=* 2707). In addition, although the number of patients included in the cardiovascular meta-analysis was larger (*n* *=* 9339), the total number of cardiovascular events reported was low (*n* *=* 192). The generalisability of the results of this study is limited, as data on the functional status of the patients were not available, and the vast majority of patients in the analysis (\>80 %) were Caucasian.

Conclusion {#Sec26}
==========

This pooled post hoc analysis suggests a favourable safety profile for dapagliflozin in older patients (aged ≥65 and ≥75 years) with T2DM. Safety over 2 years of treatment with dapagliflozin 10 mg was similar between older and younger patients, with comparable rates of hypoglycaemia, genital infections and urinary tract infections, low rates of volume reduction and no increased risk of bone fractures. AEs of renal function were more frequent in older patients, the majority of which were non-serious and driven by small transient changes in serum creatinine.
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